Fibromyalgia, Anxiety and Depression: The Whole-Person Clinical Picture | ALIV

Anxiety and depression occur in patients with fibromyalgia at rates two to three times higher than in the general population. This statistical reality is sometimes presented to patients in a way that implies the pain is caused by psychological distress — a framing that is both clinically inaccurate and deeply damaging to patients who have already spent years being told their pain is not real. The correct clinical framing is the opposite: fibromyalgia, anxiety, and depression share overlapping neurobiological mechanisms. They are not psychologically linked because one causes the other — they are neurologically linked because they emerge from the same dysregulated brain systems.

The Shared Neurobiology

Fibromyalgia, anxiety disorders, and depression all involve dysfunction in the central monoamine systems — the serotonin, norepinephrine, and dopamine pathways that regulate mood, arousal, attention, and pain modulation simultaneously. The descending inhibitory pain pathways that are weakened in fibromyalgia (allowing central sensitisation to amplify pain) rely on serotonin and norepinephrine as their neurotransmitters. These are the same neurotransmitters disrupted in depression and anxiety. A brain with low serotonin-norepinephrine activity does not just feel more anxious and depressed — it also modulates pain less effectively, allowing the central sensitisation of fibromyalgia to run unchecked.

This shared mechanism explains why duloxetine (an SNRI antidepressant) and milnacipran (also an SNRI) are specifically approved for fibromyalgia — not because fibromyalgia is a psychological condition requiring antidepressants, but because strengthening the serotonin-norepinephrine descending inhibitory pathway simultaneously reduces both the mood disorder and the pain disorder through the same pharmacological mechanism. The drug is not treating the psychological component of the pain; it is treating the neurochemical deficiency that causes both the pain and the mood disruption.

The HPA Axis — Stress, Pain, and Mood Together

The HPA (hypothalamic-pituitary-adrenal) axis — the stress response system — is abnormally regulated in fibromyalgia. Multiple studies show that fibromyalgia patients have altered cortisol diurnal rhythms, hyperreactive stress responses, and impaired negative feedback that normally terminates the cortisol response. This HPA hyperactivity maintains sympathetic arousal (the physiological anxiety state), disrupts sleep (by preventing the cortisol decline necessary for sleep onset), promotes neuroinflammation, and maintains the central sensitisation of pain. The result is a biological state that feels simultaneously anxious, exhausted, and in pain — because the same system dysregulation is producing all three simultaneously.

Addressing HPA axis hyperactivity is therefore relevant to all three conditions at once. Approaches with evidence for HPA normalisation in fibromyalgia include: mindfulness-based stress reduction (MBSR), which has demonstrated reductions in cortisol reactivity and fibromyalgia symptom burden in clinical trials; regular graded aerobic exercise, which normalises HPA feedback; magnesium supplementation, which blunts cortisol responses to stressors; and sleep improvement, which allows the nocturnal HPA downregulation that resets the system daily. See: the pain-sleep-fatigue cycle in fibromyalgia.

What This Means for Management

A fibromyalgia patient with coexisting anxiety and depression is not more "psychological" and does not need less medical management — they need more comprehensive management that addresses all three dimensions simultaneously rather than in sequence. Treating pain while ignoring depression produces incomplete responses in both; treating depression while ignoring the pain produces the same result. The ALIV approach to fibromyalgia recognises this integration: the Fibromyalgia Relief IV addresses the nutritional and biochemical dimension; we work alongside the patient's psychiatric or psychological support for the mood dimension; and we guide the movement and sleep components that address the HPA axis. No single provider can address all dimensions, but coordinating them is the clinical responsibility of the managing team.

Should I see a psychiatrist for fibromyalgia?

For patients with fibromyalgia and significant anxiety or depression — clinically significant, not just the understandable distress of living with chronic pain — a psychiatric evaluation adds genuine clinical value. A psychiatrist can prescribe the SNRIs (duloxetine, milnacipran) that have both fibromyalgia and mood disorder evidence; assess for specific anxiety or mood disorders that may benefit from specific medications; and coordinate with psychological therapy if indicated. The psychiatric evaluation is not an alternative to fibromyalgia medical management — it is a complementary specialist piece of a multi-specialist management picture.

Is cognitive behavioural therapy useful for fibromyalgia?

Yes — CBT adapted for chronic pain (sometimes called CBT-CP or pain CBT) has a robust evidence base in fibromyalgia. It targets pain catastrophising (the amplification of pain through attention, rumination, and negative prediction), activity avoidance, sleep-disrupting beliefs, and the behavioural patterns that maintain the pain-sleep-fatigue cycle. CBT does not reduce pain by convincing the patient that pain is not real — it reduces pain by reducing the psychological amplifiers that compound central sensitisation. Multiple systematic reviews rate CBT as one of the most effective non-pharmacological interventions in fibromyalgia management.

How do I explain fibromyalgia's mental health connection to family members who think it is psychological?

The most useful framing for family members: fibromyalgia changes the brain's pain volume control, producing genuine pain from signals that would not produce pain in a healthy nervous system. The anxiety and depression that come with fibromyalgia are neurological consequences of the same brain system dysregulation — not the cause of the pain. This is similar to how heart disease produces both chest symptoms and depression simultaneously through shared cardiovascular and neurological pathways. The psychology and the pain are both real; neither causes the other. Both need management. This neuroscience-grounded explanation often achieves the reframing that patient advocacy alone cannot.

Does the fibromyalgia pain always feel worse when I am anxious?

Yes — and this is the direct clinical expression of the shared neurobiology, not a coincidence or a sign that the pain is imagined. Anxiety activates the HPA axis and sympathetic nervous system, which reduces descending pain inhibition and increases peripheral nociceptor sensitivity simultaneously. For a person with central sensitisation already running high, this anxiety-induced addition to the pain system produces measurable, predictable pain amplification. Managing anxiety is therefore a measurable pain management intervention in fibromyalgia — the pain reduction from anxiety management is physiologically real, not a matter of distraction or reframing.